Lenvatinib 10 mg capsules, 30 capsules — generic (India) (Lenvima-equivalent) Thyroid cancer Targeted cancer therapy. Drug delivery from Europe, storage conditions observed, payment upon receipt, order by calling +380996042415, Viber, WhatsApp

Indications

• for the treatment of patients with progressive, locally advanced or metastatic differentiated (papillary, follicular, H?rthle cell) thyroid carcinoma refractory to radioactive iodine;
• in combination with everolimus for the treatment of patients with advanced renal cell carcinoma after one prior course of targeted therapy with vascular endothelial growth factor receptor inhibitors.

Dosage

The drug is taken orally, once daily, at approximately the same time, regardless of food intake. The capsule should be swallowed whole with water.

The capsule can also be dissolved in water or apple juice. To do this, pour approximately 1 tablespoon of water or apple juice into a small glass and place the capsules in it without opening or breaking them. Leave the capsules in the liquid for approximately 10 minutes, then stir for approximately 3 minutes and drink the liquid. Then add approximately the same volume of liquid to the glass, rinse the glass with it, and drink the contents.

When using lenvatinib in combination with everolimus, they are taken at the same time. It is necessary to read the current instructions for medical use of everolimus.

Treatment with Lenvima® should be administered under the supervision of a physician experienced in anticancer therapy.

The recommended daily dose of Lenvima® for the treatment of patients with thyroid carcinoma is 24 mg (2 capsules of 10 mg and 1 capsule of 4 mg) once daily.

If a dose is missed by more than 12 hours, skip that dose. The next dose should be taken at the usual time.

The recommended daily dose of Lenvima® for the treatment of patients with renal cell carcinoma is 18 mg (1 capsule of 10 mg and 2 capsules of 4 mg) once daily in combination with 5 mg everolimus once daily.